Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Using a glucose measurement system in intensive care for patients with shock

Official title: Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine

Run by Centre Hospitalier Universitaire de Nice · NCT04910841 · Data updated 2026-11-12

This study is testing a new glucose monitoring system to see if it can help make checking blood sugar easier and more comfortable for patients in intensive care who are dealing with septic shock.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment55 (estimated)
SponsorCentre Hospitalier Universitaire de Nice
Academic / other
Locations1 site (Nice)
StatusRecruiting
StartedSeptember 11, 2023
Main results expectedSeptember 2026
Study endsSeptember 2026
Registry record updatedMay 22, 2026
Trial IDNCT04910841 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients in septic shock with arterial hypotension requiring noradrenaline and hyperglycemia needing insulin therapy.

Probably not a fit

Patients who are under guardianship, pregnant, or breastfeeding may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility of the 'CGM GUARDIAN 2' system for monitoring glucose levels in patients experiencing hyperglycemia due to septic shock in intensive care units. The traditional method of blood glucose monitoring involves painful capillary sampling every two hours, which can lead to discomfort and sleep disturbances. The 'CGM GUARDIAN 2' system uses a subcutaneously placed electrode to measure glucose levels in interstitial fluid, potentially reducing the need for frequent blood draws. This approach aims to improve patient comfort and glycemic control in critically ill patients.

Why it matters

Potential benefit: If successful, this study could enhance glucose monitoring in intensive care, leading to better management of hyperglycemia and improved patient outcomes.

How similar studies have gone: While the use of continuous glucose monitoring systems has been validated in diabetic patients, this specific application in intensive care settings is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient in septic shock
* Arterial hypotension requiring noradrenaline
* Hyperglycaemia requiring insulin therapy

Exclusion Criteria:

* Patients under guardianship, curatorship or deprived of liberty
* Pregnant or breastfeeding women

Where it's running

  • CHU de Nice
    Nice, France
    Recruiting

Study contacts

  • Principal investigator: Florent BILGER — Centre Hospitalier Universitaire de Nice
  • Study coordinator: Florent BILGER
  • Email: bilger.f@chu-nice.fr
  • Phone: 492035510

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.